Paramount-Warner Merger Puts Remedy Design at the Center of Antitrust Review 

European regulators approved the transaction with structural commitments. The U.S. Department of Justice did not bring a federal challenge. But a coalition of state attorneys general persuaded a federal judge to pause closing while their Clayton Act claims are reviewed, and the United Kingdom is still examining the deal. 

The proposed $110 billion acquisition of Warner Bros. Discovery by Paramount Skydance now presents the real question in merger enforcement: what remedy, if any, actually solves the competitive problem before the companies are allowed to combine? 

On July 22, the European Commission approved the transaction under the EU Merger Regulation after Paramount agreed to commitments designed to preserve competition in theatrical film distribution in Europe. The same week, a federal judge in California granted a temporary restraining order preventing the deal from closing while the court considers a preliminary injunction request brought by a coalition of 12 state attorneys general. 

Europe answered that question one way. It approved the transaction after Paramount agreed to commitments aimed at preserving competition in theatrical film distribution. A federal court in California answered it another way, pausing closing because the state plaintiffs raised serious antitrust questions and because post-closing integration could make later relief difficult. 

For business attorneys and dealmakers, the lesson is practical: remedy design is not a side issue in merger review. It can determine whether a transaction closes, whether it closes with conditions, or whether a court preserves the status quo while the competitive risk is tested. For competitors and fans of fair market competition, increased scrutiny of such mega deals — if it persists — is welcome news.

Bottom line: No single enforcer gets the first and final word in a transaction of this scale. DOJ clearance matters, but it does not bind state attorneys general, foreign competition authorities, courts, or public-interest reviewers. A fix that works for one reviewer may not satisfy another. 

Why did Europe approve Paramount-Warner with conditions?

According to the European Commission, its investigation examined the effects of the merger across film production, film distribution, audiovisual content licensing, television channels, and streaming services. 

The Commission found that sufficient competitors would remain in film production and other audiovisual markets after the merger, including Disney, Universal, Sony, Amazon MGM, Lionsgate, A24, and European studios. But it identified a specific problem in theatrical film distribution in countries where Paramount works through United International Pictures, or UIP, a joint venture with Universal. Adding Warner’s film portfolio to that arrangement, the Commission concluded, could increase concentration and transparency in ways that would harm cinema operators and consumers. 

As the Commission explained: “The transaction [in its original form] would have meant Warner’s films were also distributed via UIP and, without the commitments, it would have led to worse rental and distribution terms for cinema operators, ultimately disadvantaging consumers.” 

To address those concerns, Paramount agreed to: 

• Terminate its ownership stake in UIP within 13 months of closing; 

• Refrain for 10 years from entering into agreements with Universal to jointly distribute films in the European Economic Area; 

• Maintain certain separation requirements involving Warner’s and Paramount’s distribution arrangements in designated European countries; and 

• Submit to monitoring by an independent trustee. 

The Commission concluded that these commitments “fully address the competition concerns” identified during the investigation and approved the transaction subject to compliance with those commitments. Put simply, the European approach is: identify the problem, require a targeted structural fix, and approve the deal only if the remedy removes the competitive concern. 

What did the DOJ do?

The U.S. Department of Justice’s Antitrust Division did not bring a federal challenge. That is an important factual distinction. 

It is not, however, the end of the analysis. State attorneys general have independent authority to bring federal antitrust claims, and foreign competition authorities apply their own merger-control rules. DOJ clearance may remove one obstacle without answering every remedy question. 

Why did a U.S. court hit pause on the Paramount-Warner merger?

The American court proceeding took a different path. In State of California et al. v. Paramount Skydance Corporation et al., a coalition of 12 state attorneys general challenged the merger under Section 7 of the Clayton Act. Judge Araceli Martínez-Olguín granted a temporary restraining order on July 20 preventing the parties from closing the transaction or integrating operations while the litigation proceeds. 

The judge concentrated on the market for wide-release theatrical film distribution and found that the states had introduced “compelling evidence” suggesting the combined company would possess a “substantial” 27% market share and substantially increase market concentration.  

The court concluded that the states had raised at least “serious questions going to the merits” of their antitrust claims and that temporary relief was justified while the case proceeds. Along with whether the merger violates antitrust law, the court also left alone Paramount’s arguments regarding the evolving streaming marketplace.  

The “Unscramble the Egg” Problem 

The order turned on a classic merger-enforcement concern: if the parties close first and litigate later, the chances of effective relief may evaporate. 

Judge Martínez-Olguín accepted the states’ argument that allowing the merger to close could make effective relief impossible later, citing the sharing of competitively sensitive information, operational integration, and workforce consolidation. The merger could be “difficult, if not impossible, to unwind” after closing, the judge wrote, noting prior cases recognizing the challenge of attempting to “unscramble the egg” after companies merge. 

What is the status of the UK’s review of the Paramount-Warner merger?

The United Kingdom investigation is interesting because it sees this as a media merger, not an ordinary industrial combination. The Competition and Markets Authority opened a Phase 1 merger inquiry in June 2026, with an initial decision deadline in August. Separately, the UK Culture Secretary indicated that the transaction may warrant public-interest scrutiny involving media plurality and the range of services available to UK audiences, including television, sports, news, children’s programming, and streaming services. 

That distinction is important in the UK. Competition review asks whether a deal may substantially lessen competition. Media-merger public-interest review can also ask whether the transaction affects plurality, editorial independence, access to news, or the diversity of voices available to audiences. Those questions can change both the politics and the remedy discussion. 

Who would be most affected by the Paramount-Warner merger? 

Cinema Operators. European regulators specifically focused on the risk that greater concentration in film distribution could result in less favorable rental and distribution terms for movie theaters. The remedies imposed by the Commission were designed to address that concern. Cinema operators therefore have a direct stake in whether those remedies ultimately prove effective. 

Competing Studios and Distributors. Major competitors including Disney, Universal, Sony, Amazon MGM, Lionsgate, and independent distributors are watching closely. Stopping or restructuring a deal that would unlawfully increase concentration can be good for competitors, but more importantly it can be good for competition itself by preserving independent decision-making, bargaining pressure, and alternatives for theaters, distributors, creators, advertisers, and consumers. Both the European Commission and the U.S. court focused on theatrical distribution markets, suggesting that traditional film distribution remains a significant area of antitrust concern even in the streaming era. 

Creators, Advertisers, Content Buyers, and Consumers. Creative professionals, advertisers, distributors, content buyers, and consumers all have a stake in whether consolidation reduces opportunities, bargaining leverage, content availability, or competitive pressure. While the Commission and the California court focused principally on distribution markets, broader media concentration can affect the ecosystem in which films, television programming, advertising, and streaming services are bought, sold, financed, and consumed. 

Companies Planning Future Mergers. Perhaps the most important audience is corporate dealmakers themselves. This case shows why remedy strategy must be built into the transaction from the beginning. Parties need to consider whether potential concerns can be solved through divestitures, licensing commitments, hold-separate arrangements, termination of joint ventures, or other structural changes—and whether those fixes will be credible before agencies, courts, customers, and competitors. 

Investors and Lenders. Merger uncertainty affects timing, closing risk, financing assumptions, valuation, outside dates, termination rights, and ticking fees. Even a temporary pause can matter. 

Why does remedy design matter when addressing anticompetitive concerns with a merger?  

Remedy design is the hinge. The larger lesson is not simply that different regulators can reach different procedural outcomes. It is that the strength, durability, and administrability of the proposed remedy can decide whether a deal is allowed to proceed, delayed, narrowed, or stopped. 

A remedy must do more than sound workable. It must eliminate the competitive concern in a way that does not depend on regulators repeatedly policing the merged company’s business decisions. A commitment that satisfies one authority may still leave another enforcer or court asking whether the fix is too fragile, too dependent on future behavior, or too difficult to enforce after closing. 

The distinction between structural and behavioral matters. Structural remedies—divestitures, asset sales, or the unwinding of problematic relationships—seek to remove the competitive problem at its source. Behavioral remedies, by contrast, often depend on future promises, monitoring, compliance disputes, and continuing oversight of how the merged company conducts business. 

That distinction is not academic. Antitrust agencies are law enforcers; they are not intended to serve as monitors roaming the halls of private companies. A remedy that requires years of oversight, monitoring, enforcement, and litigation may leave the public with the burden of supervising a merger that should have been fixed structurally—or stopped—before closing. 

Stopping a deal is not only about protecting rivals. If a merger would unlawfully reduce competition, blocking it—or requiring a structural fix before closing—can protect the competitive process itself. That may benefit competitors, but the antitrust point is broader: preserving rivalry can help maintain bargaining pressure, customer choice, innovation incentives, and market discipline. 

Intense scrutiny is good for competition. It can force the parties to confront the competitive problem before closing, not after the market has already been reshaped. The European Commission required changes to the distribution relationship that created the concern. The U.S. court preserved the status quo until it could decide whether effective relief would remain possible. 

Not every large merger should be blocked, of course. But if there are real anticompetitive concerns, a remedy must address them before companies are allowed to combine in ways that cannot realistically be undone. 

Sources: European Commission, Case M.12278 (Paramount/Warner); State of California et al. v. Paramount Skydance Corporation et al., No. 4:26-cv-07116-AMO (N.D. Cal. July 20, 2026).  

Edited by Tom Hagy, Editor-in-Chief, Mogin Law Blog.